Compile Data Set for Download or QSAR
Report error Found 276 Enz. Inhib. hit(s) with all data for entry = 11558
TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619376(US20230295140, Example 1 | (E)-2-(((2- butylbenzo[...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] A(Human)
Acucela

US Patent
LigandPNGBDBM619376(US20230295140, Example 1 | (E)-2-(((2- butylbenzo[...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Acucela

US Patent
LigandPNGBDBM619376(US20230295140, Example 1 | (E)-2-(((2- butylbenzo[...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619540(US20230295140, Example 2 | (E)-2-(((2-butyl-7-fluo...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Acucela

US Patent
LigandPNGBDBM619540(US20230295140, Example 2 | (E)-2-(((2-butyl-7-fluo...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619552(US20230295140, Example 3 | (E)-2-(((2-butylbenzo[d...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Acucela

US Patent
LigandPNGBDBM619552(US20230295140, Example 3 | (E)-2-(((2-butylbenzo[d...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619553(US20230295140, Example 4 | (E)-6-((2-(aminomethyl)...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619554(US20230295140, Example 5 | (E)-6-((2-(aminomethyl)...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619555(US20230295140, Example 6 | (E)-6-((2-(aminomethyl)...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619556(US20230295140, Example 7 | (E)-2-(((7-bromo-2-buty...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] A(Human)
Acucela

US Patent
LigandPNGBDBM619556(US20230295140, Example 7 | (E)-2-(((7-bromo-2-buty...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Acucela

US Patent
LigandPNGBDBM619556(US20230295140, Example 7 | (E)-2-(((7-bromo-2-buty...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619557(BDBM626645 | (E)-2-(((2-butylbenzo[d]oxazol-5-yl)o...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Acucela

US Patent
LigandPNGBDBM619557(BDBM626645 | (E)-2-(((2-butylbenzo[d]oxazol-5-yl)o...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619558(US20230295140, Example 9 | (E)-6-((2-(aminomethyl)...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Acucela

US Patent
LigandPNGBDBM619559(US20230295140, Example 10 | (E)-2-(((2-butyl-7-met...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619560(US20230295140, Example 11 | US11787791, Example 11...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619561(US20230295140, Example 12 | US11787791, Example 12...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619562(US20230295140, Example 13 | US11787791, Example 13...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619563(US20230295140, Example 14 | US11787791, Example 14...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619564(US20230295140, Example 15 | US11787791, Example 15...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Acucela

US Patent
LigandPNGBDBM619564(US20230295140, Example 15 | US11787791, Example 15...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619566(US20230295140, Example 17 | US11787791, Example 17...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619567(US20230295140, Example 18 | US11787791, Example 18...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619568(US20230295140, Example 19 | US11787791, Example 19...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619569(US20230295140, Example 20 | US11787791, Example 20...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619570(US20230295140, Example 21 | US11787791, Example 21...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619571(US20230295140, Example 22 | US11787791, Example 22...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619572(US20230295140, Example 23 | US11787791, Example 23...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619573(US20230295140, Example 24 | US11787791, Example 24...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619574(US20230295140, Example 25 | US11787791, Example 25...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619575(US20230295140, Example 26 | US11787791, Example 26...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619576(US20230295140, Example 27 | US11787791, Example 27...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619577(US20230295140, Example 28 | US11787791, Example 28...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Acucela

US Patent
LigandPNGBDBM619577(US20230295140, Example 28 | US11787791, Example 28...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619579(US20230295140, Example 30 | US11787791, Example 30...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619580(US20230295140, Example 31 | US11787791, Example 31...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619581(US20230295140, Example 32 | US11787791, Example 32...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619582(US20230295140, Example 33 | US11787791, Example 33...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619583(US20230295140, Example 34 | US11787791, Example 34...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619584(US20230295140, Example 35 | US11787791, Example 35...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Acucela

US Patent
LigandPNGBDBM619584(US20230295140, Example 35 | US11787791, Example 35...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619585(US20230295140, Example 36 | US11787791, Example 36...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619586(US20230295140, Example 37 | US11787791, Example 37...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619587(US20230295140, Example 38 | US11787791, Example 38...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Acucela

US Patent
LigandPNGBDBM619587(US20230295140, Example 38 | US11787791, Example 38...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit MAO was determined using a modified Promega MAO-Glo assay kit. The substrate ((4S)-4,5-dihydr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619588(US20230295140, Example 39 | US11787791, Example 39...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619590(US20230295140, Example 41 | US11787791, Example 41...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

TargetAmine oxidase [copper-containing] 3(Human)
Acucela

US Patent
LigandPNGBDBM619591(US20230295140, Example 42 | US11787791, Example 42...)
Affinity DataIC50: 100nMAssay Description:The capability of compounds described herein to inhibit the enzymatic activity of vascular adhesion protein-1 (VAP-1) was determined by fluorometric ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 276 total ) | Next | Last >>
Jump to: